Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V)

Advances in Therapy
Jing LiuLixin Guo

Abstract

Many Chinese patients who are uncontrolled by oral antidiabetic drugs (OADs) receive short-term intensive insulin therapy (IIT) in hospital to rapidly relieve glucose-associated toxicity and to preserve/improve β-cell function. However, evidence for optimizing insulin algorithms for maintenance treatment after IIT is lacking. This study will compare the efficacy and safety of basal insulin-based treatment versus twice-daily premixed insulin in type 2 diabetes mellitus (T2DM) patients after short-term in-hospital IIT. This 26-week randomized, multicenter, positive-controlled, open-label, parallel-group study will enroll approximately 400 male and female patients aged 18-70 years with poorly-controlled T2DM (HbA1c > 7.5%) despite treatment with metformin plus at least one other OAD for 8 or more weeks. During a run-in period of 7-10 days, patients will be treated in-hospital with IIT comprising insulin glargine (Lantus®) once daily and insulin glulisine (Apidra®) three times daily; both regimens will be titrated daily to achieve the glycemic goal. Eligible patients will then be randomized in a 1:1 ratio to insulin glargine plus OADs or twice-daily premixed insulin (NovoLog® Mix 70/30) for 24 weeks, with metformin maintained throu...Continue Reading

References

Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Apr 23, 2005·The Cochrane Database of Systematic Reviews·T DeakinR D R R Williams
Feb 15, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·U K DashoraP D Home
Sep 22, 2007·Critical Care Medicine·Jean-Charles Preiser, Philippe Devos
Feb 11, 2010·Journal of Diabetes Science and Technology·Evan Norton
Aug 8, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ben van HoutA Simon Pickard
Sep 7, 2012·Diabetes, Obesity & Metabolism·R Retnakaran, B Zinman
Jan 10, 2014·International Journal of General Medicine·John Gerich
Dec 17, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·C M SteinR Retnakaran
Dec 30, 2014·Journal of Diabetes and Its Complications·Dragana Lovre, Vivian Fonseca
Jan 27, 2015·Clinical and Investigative Medicine. Médecine Clinique Et Experimentale·Ravi Retnakaran
Mar 31, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Chantal MathieuSamuel S Engel
Jul 28, 2016·Diabetes/metabolism Research and Reviews·Jianping Weng
Jul 28, 2016·Diabetes/metabolism Research and Reviews·Jianping WengUNKNOWN Chinese Diabetes Society
Jun 28, 2017·JAMA : the Journal of the American Medical Association·Limin WangLinhong Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.